Pharma’s opportunities to improve access to medicines in LMICs highlight key areas for action

The article highlights ongoing challenges identified in the 2024 Index, including insufficient strategies by pharma companies to improve patient access, limited representation of LMIC populations in clinical trials, and a critical lack of voluntary licensing and technology transfer in sub-Saharan Africa. It also presents recommendations from the Index, such as expanding clinical trials, improving transparency in reporting, and fostering partnerships to ensure sustainable access.